Amy Parison - 28 Mar 2025 Form 3 Insider Report for Editas Medicine, Inc. (EDIT)

Role: SVP, Chief Financial Officer
Signature: /s/ Amy Parison
Issuer symbol: EDIT
Transactions as of: 28 Mar 2025
Net transactions value: $0
Form type: 3
Filing time: 08 Apr 2025, 16:20:50 UTC
Next filing: 08 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	EDIT	Common Stock						17,952	28 Mar 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EDIT	Stock Option (right to buy)							28 Mar 2025	Common Stock	26,850	$15.83	Direct	F2
holding	EDIT	Stock Option (right to buy)							28 Mar 2025	Common Stock	6,091	$8.72	Direct	F3
holding	EDIT	Stock Option (right to buy)							28 Mar 2025	Common Stock	17,220	$9.92	Direct	F4
holding	EDIT	Stock Option (right to buy)							28 Mar 2025	Common Stock	42,880	$1.72	Direct	F5
holding	EDIT	Stock Option (right to buy)							28 Mar 2025	Common Stock	145,548	$1.72	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of (i) 4,330 shares of Common Stock and (ii) 13,622 shares of Common Stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person, for no consideration, that vest periodically subject to the Reporting Person's continued service. Each RSU represents the right to receive one share of Common Stock upon vesting.
F2	This option was granted on September 9, 2022 and is scheduled to vest over four years, with 25% of the shares having vested on August 1, 2023, and the remaining 75% of the shares vesting in equal monthly installments thereafter through August 1, 2026.
F3	This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.
F4	This option was granted on March 2, 2024 and is scheduled vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028.
F5	This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026.
F6	This option was granted on March 8, 2025 and is scheduled to vest over four years, in equal monthly installments beginning on April 8, 2025 through March 8, 2029.